Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 711 to 720 of 2245 total matches.

In Brief: Concerns about Oseltamivir (Tamiflu)

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2015  (Issue 1460)
by the FDA. It will be reviewed in our February 2, 2015 issue.) 1. Antiviral drugs for seasonal influenza ...
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk patients with confirmed or suspected influenza illness, citing the British Medical Journal and The Cochrane Collaboration, which have contended that there is no acceptable evidence that the drug prevents complications or hospitalizations and have questioned the completeness of the results of controlled trials conducted by the manufacturer (Roche).
Med Lett Drugs Ther. 2015 Jan 19;57(1460):14 | Show Introduction Hide Introduction

Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2015  (Issue 1460)
Lipodystrophy Table 1. Pharmacology Drug class Leptin analog Route Subcutaneous Formulation 11.3 mg ...
Metreleptin (Myalept – Amylin), a recombinant leptin analog produced in E. coli, has been approved by the FDA to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It has not been approved to date for the treatment of partial lipodystrophies, including those associated with the use of protease inhibitors in patients with HIV. Metreleptin is approved in Japan for the treatment of any lipodystrophy disorder.
Med Lett Drugs Ther. 2015 Jan 19;57(1460):13-4 | Show Introduction Hide Introduction

Oritavancin (Orbactiv) for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.1,2 Oritavancin ...
The FDA has approved oritavancin (Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria in adults. It is the third lipoglycopeptide antibiotic to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):3-5 | Show Introduction Hide Introduction

Olodaterol (Striverdi Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
-daily use; indacaterol (Arcapta Neohaler),1 which is available as a single agent, and vilanterol ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta2-agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler), which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the...
Med Lett Drugs Ther. 2015 Jan 5;57(1459):1-3 | Show Introduction Hide Introduction

Trumenba: A Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
the importation and investigational use of Bexsero in two outbreaks of serogroup B meningococcal disease.1 ...
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):5-6 | Show Introduction Hide Introduction

Triumeq: A 3-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.1 Pronunciation Key ...
The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):7-8 | Show Introduction Hide Introduction

Siltuximab (Sylvant) for Treatment of Multicentric Castleman's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
after a median follow-up of 5.1 years.4 DOSAGE AND COST — Sylvant is supplied in 100- and 400-mg ...
The FDA has approved the interleukin-6 (IL-6) antagonist siltuximab (Sylvant – Janssen), a recombinant chimeric (human-mouse) monoclonal antibody, for treatment of multicentric Castleman's disease (MCD) in patients who are HIV negative and human herpesvirus-8 (HHV-8) negative. It is the first drug to be approved for this indication.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):e8 | Show Introduction Hide Introduction

Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014  (Issue 1457)
should be added to metformin, which is already Table 1. Canagliflozin, Dapagliflozin and Combinations ...
The FDA has approved fixed-dose combinations of metformin with either canagliflozin (Invokamet) or dapagliflozin (Xigduo XR) for treatment of patients with type 2 diabetes not adequately controlled with any one of these drugs, or in those already being treated with both metformin and either canagliflozin or dapagliflozin.
Med Lett Drugs Ther. 2014 Dec 8;56(1457):124-5 | Show Introduction Hide Introduction

Two New Drugs for Idiopathic Pulmonary Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014  (Issue 1457)
5-year survival rate is about 44%.1 MECHANISM OF ACTION — The exact mechanism of action ...
The FDA has approved 2 oral drugs for treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone (Esbriet) has been available in Europe since 2011 and in Canada since 2012. Nintedanib (Ofev) is available only in the US.
Med Lett Drugs Ther. 2014 Dec 8;56(1457):123-4 | Show Introduction Hide Introduction

Secondary Prevention of Stroke

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014  (Issue 1457)
ischemic attack (TIA).1 ASPIRIN — Aspirin monotherapy has been shown to reduce the risk of secondary ...
Recent guidelines from the American Heart Association and American Stroke Association reviewed antithrombotic therapy options for secondary prevention of stroke in patients who have had a stroke or transient ischemic attack (TIA).
Med Lett Drugs Ther. 2014 Dec 8;56(1457):125-6 | Show Introduction Hide Introduction